Company’s Radiology and Pathology Solutions Expand Clinician Capacity, Increase Operational Efficiency, and Improve Early Disease Diagnosis
Harrison.ai, a leading global healthtech company and developer of AI-powered medical diagnostic support and workflow solutions, announced today the accelerated expansion of its operations into the United States, a move supported by US$112 million of Series C funding. The funding will also fuel the company’s product roadmap and continued growth in the UK, EMEA and APAC. The round is one of the largest capital raises in the medical AI space over the past twelve months.
The round was co-led by Aware Super, ECP and existing investor, Horizons Ventures. New investors, such as Australia’s National Reconstruction Fund Corporation (NRFC), Ord Minnett and Wollemi Capital Group also participated, along with existing investors including Blackbird Ventures and Alpha JWC Ventures. Harrison.ai’s total capital raised to date exceeds US$240 million.
Harrison’s technology in radiology and pathology assists clinicians with identifying signs of cancer and other critical illnesses earlier, improving treatment decisions and patient outcomes. It uses AI to analyze CT scans, X-rays, and pathology slides, supporting clinicians in detecting and diagnosing medical conditions faster and more accurately.
Harrison.ai aims to address the global shortage of 1.5 million skilled clinicians and the surge in demand for diagnosis impacting both developed and under-developed healthcare systems. In the United States, according to a study by the Association of American Medical Colleges, there are 11 radiologists per 100,000 people. More than two-thirds of the world’s pathologists are distributed across only 10 countries.
“The growing demand for equitable and effective healthcare calls for advanced systems like AI to enhance human diagnostics and address disparities in access to care,” said Dr. Aengus Tran, Harrison.ai Co-Founder and Chief Executive Officer. “Harrison.ai meets this need by developing clinical-grade AI models designed to improve capacity. We look forward to bringing our life-saving technology to healthcare systems in the U.S. and continuing our expansion across the globe.”
“Harrison.ai’s ability to harness the rapidly evolving opportunities out of digitization and AI is remarkable and we look forward to supporting their long-term application to the healthcare sector,” said Alvin Chan, Portfolio Manager – Direct Equities at Aware Super, one of Australia’s largest pension funds managing A$190 billion on behalf of its 1.15 million members.
Harrison.ai solutions are driving a significant improvement through early lung cancer detection within hospital systems. Radiologists using Harrison.ai’s technology have seen an over 45% increase in diagnostic accuracy1. Studies indicate that Harrison’s AI for chest radiography can aid in the early detection of lung cancer, showing that over 32% of lung cancer cases could have been diagnosed sooner—by an average of 16 months2. Additionally, it has been shown to enhance clinical outcomes by increasing the proportion of cases detected at treatable stages by more than 26%3.
Over 1,000 healthcare facilities worldwide support the care of more than six million patients each year with Harrison.ai solutions. Its radiology solution (Annalise.ai) is available to 1 in 2 radiologists in Australia, and processes scans for more than 45 Trusts and over 131 public hospitals in the United Kingdom, including 35% of chest X-ray volume in England. It also powers all CT Brain scans across public accident and emergency (A&E) systems in Hong Kong and was recently selected by the Danish public healthcare system to help clinicians deliver better outcomes.
Further accelerating its global commercialization efforts, Harrison.ai is establishing a North American presence in Boston. The company will focus on building its U.S. operations and growing the Harrison.ai customer base. The company has already received 12 FDA clearances, and one of its CT Brain algorithms has FDA Breakthrough Device Designation and Medicare reimbursement through the New Technology Add-on Payment (NTAP).
Harrison.rad.1, its radiology-specific vision-language technology, was developed last year and is now accessible to researchers, industry partners, regulators, and others in the AI community.
Harrison.ai was invited to participate in the Healthcare AI Challenge hosted by Mass General Brigham, where it joins Microsoft, OpenAI, Google, and others in a series of events to assess AI technology and generate insights from healthcare professional participants. This initiative is intended to help inform the community and industry to ensure adherence to high standards for efficacy and safety for AI in medical imaging and healthcare more broadly.
